Research Center: Henry Ford Medical Center
Location: 39450 W 12 Mile Rd, Novi, Michigan 48377
Lead Researcher: Christopher Drake, PhD
IRB: This study has been reviewed and approved by the Henry Ford Health IRB and Advarral IRB
About the Study
Did you know that many new mothers face challenges with postpartum depression (PPD), and traditional treatments don’t always help? That’s why researchers are exploring RE104, an investigational psychedelic medication similar to psilocybin. This study aims to see if a single dose of RE104 could help ease PPD symptoms.
Join Henry Ford Medical Center researchers in this potentially groundbreaking study that could change the future of PPD treatment! Discover if you qualify. Join today!
Why Participate?
- Participants may receive a new potential treatment for postpartum depression at no cost.
- Participants may earn up to $918 for their involvement, receiving $150 for each attended study visit, with payments made at the end of each visit. If they do not complete the study, they will still be compensated for the visits they completed.
- Participants may experience improvements in symptoms related to PPD.
- Participants will be contributing valuable information that may benefit those with postpartum depression in the future.
- Participants will be helping to advance medical research.
Your Rights
- If you decide to participate in the study and later feel that you no longer wish to be part of it, you can withdraw at any time.
- Any information that you provide will be kept strictly confidential, except as required by law.
- Qualified health professionals will monitor your health as it relates to the study.
Who Can Participate?
- Must be experiencing postpartum depression
- Must have started feeling symptoms during the second or third trimester or within the first month following birth
- Must not be more than 12 months postpartum
- Must not be breastfeeding or must be willing to stop breastfeeding if screened for the study
- Must not have ever been diagnosed with postpartum psychosis
- Must be willing to come to the research site for 8-10 in-person visits
More Study Details
The study team will explain the research in its entirety but some details are:
- Participants will evaluate the safety and efficacy of two different doses of RE104, receiving either a low dose of 1.5 mg or a high dose of 30 mg, administered as a one-time injection in the upper arm at the clinic by qualified study staff.
- Participants must be randomly assigned to one of the two dosage groups through a coin-toss method, ensuring that neither the participant nor the study doctor will know which dose is being administered unless a medical emergency arises.
- Participants will commit to a total duration of up to 53 days, attending 8-10 scheduled visits, including 4 follow-up appointments conducted via telephone.
About the Research Center
Henry Ford Medical Center
The Henry Ford Sleep Research Center, founded in 1978, is one of the first sleep disorders centers in the United States and is consistently one of the top sleep research facilities in the nation. It is home of the Center for Behavioral Circadian Medicine and the Perinatal Sleep Health Institute and now has locations across Southeast Michigan. Our mission is to continuously improve sleep-wake health through the production, incorporation and dissemination of sleep research. We strive to foster multidisciplinary collaboration across HFH Women’s Health Clinics, behavioral health, and sleep medicine to support research and quality enhancement initiatives to improve care for pregnant and postpartum patients.